A detailed history of Palisades Hudson Asset Management, L.P. transactions in Amgen Inc stock. As of the latest transaction made, Palisades Hudson Asset Management, L.P. holds 758 shares of AMGN stock, worth $199,490. This represents 0.1% of its overall portfolio holdings.

Number of Shares
758
Previous 662 14.5%
Holding current value
$199,490
Previous $207,000 17.87%
% of portfolio
0.1%
Previous 0.1%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$309.38 - $337.38 $29,700 - $32,388
96 Added 14.5%
758 $244,000
Q2 2024

Jul 31, 2024

SELL
$262.75 - $319.31 $32,843 - $39,913
-125 Reduced 15.88%
662 $207,000
Q4 2023

Feb 12, 2024

SELL
$255.7 - $288.46 $134,242 - $151,441
-525 Reduced 40.02%
787 $227,000
Q1 2023

Apr 26, 2023

SELL
$225.79 - $275.2 $5,193 - $6,329
-23 Reduced 1.72%
1,312 $317,000
Q4 2022

Feb 08, 2023

BUY
$229.03 - $291.01 $2,977 - $3,783
13 Added 0.98%
1,335 $350,000
Q3 2022

Oct 28, 2022

SELL
$224.46 - $253.15 $11,223 - $12,657
-50 Reduced 3.64%
1,322 $298,000
Q2 2022

Aug 10, 2022

BUY
$230.71 - $256.74 $6,921 - $7,702
30 Added 2.24%
1,372 $334,000
Q1 2022

Apr 27, 2022

BUY
$219.27 - $242.57 $8,551 - $9,460
39 Added 2.99%
1,342 $324,000
Q1 2021

May 10, 2021

SELL
$221.91 - $258.6 $18,196 - $21,205
-82 Reduced 5.92%
1,303 $324,000
Q4 2019

Jan 30, 2020

SELL
$189.21 - $243.2 $7,568 - $9,728
-40 Reduced 2.81%
1,385 $334,000
Q1 2019

Apr 23, 2019

SELL
$180.87 - $203.88 $54,261 - $61,164
-300 Reduced 17.39%
1,425 $271,000
Q3 2018

Nov 08, 2018

SELL
$185.29 - $208.89 $40,763 - $45,955
-220 Reduced 11.31%
1,725 $357,000
Q3 2017

Nov 06, 2017

BUY
$167.29 - $191.0 $325,379 - $371,495
1,945
1,945 $362,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Palisades Hudson Asset Management, L.P. Portfolio

Follow Palisades Hudson Asset Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palisades Hudson Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Palisades Hudson Asset Management, L.P. with notifications on news.